OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 44,784 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) by 140.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,646 shares of the company's stock after buying an additional 44,784 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.08% of Arcus Biosciences worth $1,141,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Arcus Biosciences by 2.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock worth $506,000 after buying an additional 833 shares during the period. JPMorgan Chase & Co. increased its holdings in Arcus Biosciences by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company's stock valued at $668,000 after buying an additional 1,117 shares during the last quarter. R Squared Ltd acquired a new position in Arcus Biosciences in the fourth quarter valued at approximately $26,000. Teacher Retirement System of Texas boosted its position in shares of Arcus Biosciences by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company's stock worth $223,000 after buying an additional 2,410 shares during the period. Finally, Handelsbanken Fonder AB lifted its position in Arcus Biosciences by 11.2% in the fourth quarter. Handelsbanken Fonder AB now owns 24,800 shares of the company's stock worth $369,000 after purchasing an additional 2,500 shares during the period. Institutional investors and hedge funds own 92.89% of the company's stock.

Insider Buying and Selling at Arcus Biosciences

In other Arcus Biosciences news, Director Yasunori Kaneko acquired 20,000 shares of the company's stock in a transaction on Thursday, February 27th. The shares were bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the acquisition, the director now directly owns 28,400 shares of the company's stock, valued at $285,704. This trade represents a 238.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Terry J. Rosen purchased 19,800 shares of Arcus Biosciences stock in a transaction on Thursday, February 27th. The shares were acquired at an average price of $10.18 per share, with a total value of $201,564.00. Following the transaction, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.80. This trade represents a 0.78% increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on RCUS. Wells Fargo & Company lowered their target price on shares of Arcus Biosciences from $29.00 to $26.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 7th. Barclays decreased their price target on shares of Arcus Biosciences from $29.00 to $14.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Wedbush reissued an "outperform" rating and set a $33.00 price target on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Morgan Stanley decreased their price target on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Finally, The Goldman Sachs Group decreased their target price on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 8th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $25.67.

Arcus Biosciences Stock Performance

Shares of RCUS stock traded up $0.10 during trading hours on Monday, hitting $8.66. The company's stock had a trading volume of 236,031 shares, compared to its average volume of 838,439. The company has a 50 day moving average of $8.28 and a 200 day moving average of $12.09. Arcus Biosciences, Inc. has a 12-month low of $6.50 and a 12-month high of $18.98. The stock has a market cap of $916.43 million, a PE ratio of -2.75 and a beta of 0.88. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.12). The firm had revenue of $28.00 million for the quarter, compared to analyst estimates of $38.61 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Arcus Biosciences's revenue for the quarter was down 80.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.05) earnings per share. On average, sell-side analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.